BioHistory Moment: Diamond v. Chakrabarty case argued before U.S. Supreme Court

On March 17, 1980, the Diamond v. Chakrabarty case was argued before the U.S. Supreme Court regarding the patentability of genetically altered microorganisms.

In 1972, Chakrabarty filed a patent application assigned to the General Electric Co. for a human-made genetically engineered bacterium capable of breaking down multiple components of crude oil. The application asserted 36 claims related to Chakrabarty's invention of a bacterium from the genus Pseudomonas containing at least two stable energy-generating plasmids, each of said plasmids providing a separate hydrocarbon degradative pathway.

On June 16, 1980, the U.S. Supreme Court upheld five-to-four the patentability of genetically altered organisms, opening the door to greater patent protection for any modified life forms. Chief Justice Warren Burger delivered the opinion of the Court, in which justices Potter Stewart, Harry Blackmun, William Rehnquist, and John Paul Stevens joined. William Brennan filed the dissenting opinion, in which Byron White, Thurgood Marshall, and Lewis Powell joined.

Learn about Seattle's PNDRI Life Sciences Incubator Building

Learn about biotechnology, medical device and pharmaceutical facilities available for sale, lease or sublease in Washington, regionally or nationwide.

Industry News...

Free News Release Posting & Archiving Service


• Additional $162 million in Recovery Act investment to advance health IT  U.S. Department of Health and Human Services Secretary Kathleen Sebelius announced awards to help states facilitate health information exchange and advance health information technology (health IT).
  Dept. of Health & Human Services  March 15, 2010  
  
  
• Lilly to acquire global license to AXIRON testosterone solution from Acrux  Eli Lilly and Company and Acrux announced that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON(TM)).
  Eli Lilly and Company  March 15, 2010  
  
  
• Intensive Lipitor therapy was associated with reduced risk of cardiovascular events  Lipitor(R) (atorvastatin calcium) 80 mg was associated with a significantly reduced risk of major cardiovascular events compared with Lipitor 10 mg among patients with both coronary heart disease (CHD) and chronic kidney disease (CKD) who were obese or had metabolic syndrome.
  Pfizer Inc.  March 15, 2010  
  
  
• Amylin, Lilly and Alkermes receive Complete Response Letter from FDA for Exenatide  Amylin Pharmaceuticals, Eli Lilly and Company and Alkermes announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON(TM) (exenatide for extended-release injectable suspension).
  Eli Lilly and Company  March 15, 2010  
  
  
• Peer-reviewed research elucidates function of Hsp27  OncoGenex Pharmaceuticals announced that two peer-reviewed manuscripts have been published that provide additional insight into the function of Heat Shock Protein 27 (Hsp27) and its role in promoting tumor resistance to cancer treatment.
  OncoGenex  March 15, 2010  
  
  

More... | Submit News Release | Advertising...

New Job Postings...

The Recruiter’s Studio: People, Careers, Conversations

• Intern/volunteer Fred Hutchinson Cancer Research Center (WA)
• Research Technician II/III Fred Hutchinson Cancer Research Center (WA)
• Business Development Associate Integrated Diagnostics, Inc. (WA)
• Bioinformatics Scientist Institute for Systems Biology (WA)
• Director of Human Resources Institute for Systems Biology (WA)

More... | Job Advertising...

New Facilities Available...

ATC clean room constructors...validation guaranteed!

• 890 Embarcadero Road Property -- West Sacramento, CA
• CompleGen Lab/Office Space -- Seattle, WA
• Life Sciences Incubator -- Seattle, WA
• University of Iowa Oakdale Research Park Biotech Building -- Coralville, IA
• University of Iowa Oakdale Research Park BioVentures Center -- Coralville, IA

More... | Facility Advertising...

Upcoming Events...

• 03/16/2010: ORCA Monthly Meeting: Requirements & Best Practices for Management Review (Part 3 of 4 in Medical Device Quality System Series)
• 03/16/2010: Pharma & Biotech Supply Chain Asia 2010
• 03/16/2010: Global health as an Investment Opportunity
• 03/16/2010: Preparing an R&D Product for Out-Licensing and Due Diligence
• 03/16/2010: Life Science Innovation Northwest

More... | Submit Event | Event Advertising...